Sherene Min

5.6k total citations · 3 hit papers
46 papers, 3.3k citations indexed

About

Sherene Min is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Sherene Min has authored 46 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Infectious Diseases, 33 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Sherene Min's work include HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (33 papers) and HIV/AIDS Research and Interventions (17 papers). Sherene Min is often cited by papers focused on HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (33 papers) and HIV/AIDS Research and Interventions (17 papers). Sherene Min collaborates with scholars based in United States, United Kingdom and Japan. Sherene Min's co-authors include Ivy Song, Yu Lou, Tamio Fujiwara, Stephen C. Piscitelli, Clare Brennan, Julie Borland, Franco Maggiolo, François Raffi, Brian Wynne and Shuguang Chen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Sherene Min

42 papers receiving 3.3k citations

Hit Papers

Dolutegravir plus Abacavir–Lamivudine for the Treatment o... 2013 2026 2017 2021 2013 2013 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
    2013 593 citations Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine profile →
  2. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
    2013 404 citations François Raffi, Anita Rachlis et al. The Lancet profile →
  3. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    2014 350 citations Bonaventura Clotet, Judith Feinberg et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sherene Min United States 24 3.1k 2.3k 654 556 510 46 3.3k
Thomas N. Kakuda United States 29 2.3k 0.8× 1.5k 0.7× 620 0.9× 889 1.6× 339 0.7× 109 3.1k
Brian Wynne United States 25 2.0k 0.6× 1.4k 0.6× 617 0.9× 651 1.2× 185 0.4× 70 2.6k
Ivy Song United States 23 1.7k 0.6× 1.1k 0.5× 295 0.5× 487 0.9× 365 0.7× 52 2.1k
Daniel Podzamczer Spain 29 3.3k 1.1× 2.4k 1.0× 1.5k 2.2× 726 1.3× 191 0.4× 144 4.0k
Pieter L. Meenhorst Netherlands 29 1.7k 0.5× 1.3k 0.6× 349 0.5× 567 1.0× 167 0.3× 51 2.3k
Camlin Tierney United States 21 1.7k 0.6× 1.2k 0.5× 899 1.4× 383 0.7× 115 0.2× 60 2.4k
Joseph M. Custodio United States 18 1.4k 0.4× 874 0.4× 556 0.9× 234 0.4× 247 0.5× 40 2.0k
Anthony J. Japour United States 23 2.8k 0.9× 2.4k 1.1× 680 1.0× 524 0.9× 119 0.2× 34 3.2k
Andrew Mulato United States 22 1.6k 0.5× 1.2k 0.5× 174 0.3× 586 1.1× 315 0.6× 33 2.1k
Laura Waters United Kingdom 25 1.6k 0.5× 936 0.4× 798 1.2× 472 0.8× 133 0.3× 96 2.2k

Countries citing papers authored by Sherene Min

Since Specialization
Citations

This map shows the geographic impact of Sherene Min's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherene Min with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherene Min more than expected).

Fields of papers citing papers by Sherene Min

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherene Min. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherene Min. The network helps show where Sherene Min may publish in the future.

Co-authorship network of co-authors of Sherene Min

This figure shows the co-authorship network connecting the top 25 collaborators of Sherene Min. A scholar is included among the top collaborators of Sherene Min based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherene Min. Sherene Min is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Puthanakit, Thanyawee, Linda Aurpibul, S.Y. Amy Cheung, et al.. (2025). Efficacy and Safety of the Two-Drug Regimen Dolutegravir–Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 99(2). 202–210.
2.
D’Amico, Ronald, Kelong Han, Sherene Min, et al.. (2025). Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS. 39(15). 2182–2190. 1 indexed citations
3.
Buchanan, Ann M., Adrie Bekker, Hardik Chandasana, et al.. (2024). Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective. International Journal of Antimicrobial Agents. 64(4). 107306–107306. 1 indexed citations
4.
5.
Viani, Rolando M., Carmelita Alvero, Terry Fenton, et al.. (2015). Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents. The Pediatric Infectious Disease Journal. 34(11). 1207–1213. 40 indexed citations
6.
7.
Clotet, Bonaventura, Judith Feinberg, Jan van Lunzen, et al.. (2014). Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. The Lancet. 383(9936). 2222–2231. 350 indexed citations breakdown →
8.
Spreen, William, Sherene Min, Susan L. Ford, et al.. (2013). Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor. HIV Clinical Trials. 14(5). 192–203. 92 indexed citations
9.
Raffi, François, Anita Rachlis, Hans‐Jürgen Stellbrink, et al.. (2013). Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. The Lancet. 381(9868). 735–743. 404 indexed citations breakdown →
10.
Walmsley, Sharon, Antonio Antela, Nathan Clumeck, et al.. (2013). Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine. 369(19). 1807–1818. 593 indexed citations breakdown →
11.
Stellbrink, Hans-Jürgen, Jacques Reynes, Adriano Lazzarin, et al.. (2013). Dolutegravir in antiretroviral-naive adults with HIV-1. AIDS. 27(11). 1771–1778. 131 indexed citations
12.
Raffi, François, Hans Jaeger, Eugenia Quirós-Roldán, et al.. (2013). Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases. 13(11). 927–935. 269 indexed citations
13.
Lunzen, Jan van, Franco Maggiolo, José Ramón Arribas, et al.. (2011). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet Infectious Diseases. 12(2). 111–118. 226 indexed citations
14.
Song, Ivy, Julie Borland, Shuguang Chen, et al.. (2011). Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572. British Journal of Clinical Pharmacology. 72(1). 103–108. 55 indexed citations
15.
Min, Sherene, Louis Sloan, Edwin DeJesus, et al.. (2011). Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 25(14). 1737–1745. 171 indexed citations
16.
Min, Sherene, J. Rick Turner, Adel Nada, et al.. (2010). Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. American Heart Journal. 159(5). 716–729. 16 indexed citations
17.
Song, Ivy, Sherene Min, Julie Borland, et al.. (2010). The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants. The Journal of Clinical Pharmacology. 51(2). 237–242. 52 indexed citations
18.
Song, Ivy, Sherene Min, Julie Borland, et al.. (2010). Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(3). 365–367. 29 indexed citations
19.
Shelton, Mark, Susan L. Ford, Julie Borland, et al.. (2006). Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics. JAIDS Journal of Acquired Immune Deficiency Syndromes. 42(1). 61–67. 26 indexed citations
20.
Lim, Michael L., Sherene Min, Joseph J. Eron, et al.. (2004). Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(5). 1034–1040. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas N. Kakuda Breakdown of academic impact, for papers by Brian Wynne Breakdown of academic impact, for papers by Ivy Song Breakdown of academic impact, for papers by Daniel Podzamczer Breakdown of academic impact, for papers by Pieter L. Meenhorst Breakdown of academic impact, for papers by Camlin Tierney Breakdown of academic impact, for papers by Joseph M. Custodio Breakdown of academic impact, for papers by Anthony J. Japour Breakdown of academic impact, for papers by Andrew Mulato Breakdown of academic impact, for papers by Laura Waters
Rankless by CCL
2026